Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Companies Get Research Tax Break, Duty Cuts in Federal Budget

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Indian Finance Minister Palaniappan Chidambaram said a 150 percent research and development tax rebate for drug firms would be extended to contract outsourcing work at a 125 percent rebate as he slashed duties on a variety of bulk drugs and pharmaceuticals in the country's proposed $192 billion budget for the fiscal year starting April 1

You may also be interested in...



PharmAsia News India Pharma Roundup: Jubilant Organosys, Drug Price Cuts, Pharma Advisory Forum, Ranbaxy

NEW DELHI - India's Jubilant Organosys' $225 million all-cash deal for Canada's Draxis Health provides the company a path to consolidate contract manufacturing in North America with a contract in hand to launch a generic version of Johnson & Johnson's imaging agent Cardiolite in 2008 and time to mull whether to retain the company's currently high margin but increasingly competitive radiopharmaceutical business, Kotak Institutional Equities said

PharmAsia News India Pharma Roundup: Jubilant Organosys, Drug Price Cuts, Pharma Advisory Forum, Ranbaxy

NEW DELHI - India's Jubilant Organosys' $225 million all-cash deal for Canada's Draxis Health provides the company a path to consolidate contract manufacturing in North America with a contract in hand to launch a generic version of Johnson & Johnson's imaging agent Cardiolite in 2008 and time to mull whether to retain the company's currently high margin but increasingly competitive radiopharmaceutical business, Kotak Institutional Equities said

PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse

NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel